Vimab Group (VIMAB) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue fell 23.9% year-over-year to 75.3 MSEK, with operating loss of -9.9 MSEK and EPS of -0.5 SEK.

• Strategic shift towards near-shoring and electro-infrastructure increased costs in Q2 and Q3, but is expected to yield positive results from Q4 onward.

• After Q3, a letter of intent for a battery system order worth 825 MSEK was received, the largest in company history.

• Evaluation of a potential sale of Vimab AB, the largest subsidiary, is underway to strengthen financial position.

Financial highlights

• Q3 net sales: 75.3 MSEK (98.9), EBITDA: -0.8 MSEK (17.6), operating result: -9.9 MSEK (9.3), net result: -12.2 MSEK (4.7).

• Jan–Sep net sales: 237.8 MSEK (227.7), EBITDA: -3.5 MSEK (21.8), operating result: -29.8 MSEK (5.3), net result: -35.2 MSEK (-0.2).

• Cash flow from operations Q3: -6.1 MSEK (18.2); Jan–Sep: 1.9 MSEK (7.8).

• Gross margin Q3 improved to 81.8% (73.0%) due to higher service sales and billing quality.

• Personnel costs rose due to acquisitions and increased staffing.

Outlook and guidance

• Q4 has started well; management expects the strategic focus on electro-infrastructure and near-shoring to drive strong growth in coming quarters and years.

• Anticipated positive impact from the 825 MSEK battery system order, pending final agreement.